Clinical Trials Directory

Trials / Completed

CompletedNCT03155022

Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction

Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction: A Multicenter, Randomized, Controlled Clinical Trial (CARIOCA Study)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
750 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Infarct size is a major determinant of prognosis after AMI. Evidence indicates that the combination of intracoronary ischemic conditioning (ICIC) and remote ischemic conditioning (RIC) can significantly reduce infarct size in STEMI patients. Whether the combination of these two interventions may improve clinical outcome after STEMI remains unknown. The objective of the present study is to determine whether combination of ICIC and RIC can improve STEMI patients clinical outcome at 6 months.

Conditions

Interventions

TypeNameDescription
DEVICERemote ischemic conditioning and intracoronary ischemic conditioningRIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion. ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization.
DEVICEPatients with no remote ischemic conditioning and no intracoronary ischemic conditioningBrachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.

Timeline

Start date
2018-04-12
Primary completion
2023-10-03
Completion
2023-10-03
First posted
2017-05-16
Last updated
2025-08-28

Locations

4 sites across 2 countries: Belgium, France

Source: ClinicalTrials.gov record NCT03155022. Inclusion in this directory is not an endorsement.